Zhou Wen-yong, Chen Xiao-feng, Zhang Lei, Zhang Hui-jun, Wang Hai-bing, Zhang Hui, Zhao Ming-chuan, Liu Hong-cheng
Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University, Shanghai 200433, China.
Zhonghua Wai Ke Za Zhi. 2011 Sep 1;49(9):820-4.
To assess early and late outcomes of patients with minimal mediastinal lymph nodes metastasis N2 non-small cell lung cancer disease unexpectedly detected during the operation, who underwent video-assisted thoracic surgery lobectomy for clinical stage I.
This study retrospectively reviewed and analyzed the medical records of 263 patients underwent surgery between January 2004 and December 2007, who were diagnosed as having early-stage non-small cell lung cancer (clinical stage was cT1-2N0M0, stage I) before the surgery, but were found to have mini mediastinal lymph nodes metastasis disease (clinical stage was pT1-2N2M0, stage IIIa) unexpectedly detected during the operation and after the operation. All patients underwent lobectomy and systematic lymph nodes dissection as radical treatments. Among them, 63 patients underwent video-assisted thoracic surgery (VATS) lobectomy, including 37 male patients (58.7%) with a mean age of (58 ± 11) years old. Two hundred patients underwent open thoracotomy lobectomy, including 132 male patients (66%) with a mean age of (59 ± 11) years old. To compare and analyze clinical features, early and late outcomes of patients in these two groups.
A total of 263 patients with an average survival time (34.9 ± 1.2) months (median 31 months), 63 cases in VATS lobectomy group with an average survival time (40.3 ± 2.2) months (median 37 months), 200 cases in open pulmonary lobectomy group with an average survival time (33.1 ± 1.3) months (median 29 months). The 1-, 2-, 3-year over survival rate of all the patients was 92.0%, 57.4%, 29.3%. The 1-, 2-, 3-year survival rate of patients in VATS lobectomy group was 92.1%, 82.5%, 41.3%. The 1, 2, 3 year survival rate of patients in thoracotomy lobectomy group was 92.0%, 49.5%, 25.5%. There was significant difference between the two groups in this factor (χ(2) = 5.58, P = 0.018).
VATS lobectomy is feasibility and safety for unexpected mini N2 disease. Even if lymph node metastasis is unexpectedly detected during video-assisted thoracic surgery lobectomy for clinical stage I disease after rigorous evaluation of preoperative, it is no need to convert to conventional thoracotomy.
评估手术中意外发现纵隔淋巴结转移的N2期非小细胞肺癌患者(临床分期为I期)行电视辅助胸腔镜手术肺叶切除术后的早期和晚期疗效。
本研究回顾性分析了2004年1月至2007年12月期间接受手术的263例患者的病历,这些患者术前被诊断为早期非小细胞肺癌(临床分期为cT1-2N0M0,I期),但在手术中及术后意外发现有微小纵隔淋巴结转移(临床分期为pT1-2N2M0,IIIA期)。所有患者均接受肺叶切除和系统性淋巴结清扫作为根治性治疗。其中,63例患者接受电视辅助胸腔镜手术(VATS)肺叶切除术,包括37例男性患者(58.7%),平均年龄为(58±11)岁。200例患者接受开胸肺叶切除术,包括132例男性患者(66%),平均年龄为(59±11)岁。比较分析两组患者的临床特征、早期和晚期疗效。
263例患者平均生存时间为(34.9±1.2)个月(中位数31个月),VATS肺叶切除术组63例患者平均生存时间为(40.3±2.2)个月(中位数37个月),开胸肺叶切除术组200例患者平均生存时间为(33.1±1.3)个月(中位数29个月)。所有患者1年、2年、3年总生存率分别为92.0%、57.4%、29.3%。VATS肺叶切除术组患者1年、2年、3年生存率分别为92.1%、82.5%、41.3%。开胸肺叶切除术组患者1年、2年、3年生存率分别为92.0%、49.5%、25.5%。两组在该因素上有显著差异(χ(2)=5.58,P=0.018)。
VATS肺叶切除术治疗意外微小N2期疾病具有可行性和安全性。即使在对临床I期疾病行VATS肺叶切除术时意外发现淋巴结转移,经严格术前评估后也无需转为传统开胸手术。